StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Seres Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $46.64M, down 13.7% year over year. For fiscal 2025 it was $49.06M, down 24.1% from the year before. Over ten years it grew 2.6% a year on average. The highest annual figure on record is $141.89M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$49.06M-24.1%
FY2024Dec 31, 2024$64.60M-45.1%
FY2023Dec 31, 2023$117.60M+7.2%
FY2022Dec 31, 2022$109.65M-22.7%
FY2021Dec 31, 2021$141.89M+56.7%
FY2020Dec 31, 2020$90.57M+13.0%
FY2019Dec 31, 2019$80.14M-16.5%
FY2018Dec 31, 2018$95.96M+7.3%
FY2017Dec 31, 2017$89.46M+9.1%
FY2016Dec 31, 2016$81.99M+115.2%
FY2015Dec 31, 2015$38.10M+255.4%
FY2014Dec 31, 2014$10.72M+123.1%
FY2013Dec 31, 2013$4.81M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.14M-29.4%
Q1 FY2026Mar 31, 2026$13.20M+11.6%
Q4 FY2025Dec 31, 2025$11.68M-9.0%
Q3 FY2025Sep 30, 2025$12.62M-23.4%
Q2 FY2025Jun 30, 2025$12.94M-18.1%
Q1 FY2025Mar 31, 2025$11.82M-39.4%
Q4 FY2024Dec 31, 2024$12.84M-44.3%
Q3 FY2024Sep 30, 2024$16.46M-34.6%
Q2 FY2024Jun 30, 2024$15.81M-66.2%
Q1 FY2024Mar 31, 2024$19.49M-55.7%
Q4 FY2023Dec 31, 2023$23.04M-50.1%
Q3 FY2023Sep 30, 2023$25.15M-41.7%
Q2 FY2023Jun 30, 2023$46.79M+6.5%
Q1 FY2023Mar 31, 2023$43.97M+10.9%
Q4 FY2022Dec 31, 2022$46.22M+25.8%
Q3 FY2022Sep 30, 2022$43.12M+8.1%
Q2 FY2022Jun 30, 2022$43.94M+22.2%
Q1 FY2022Mar 31, 2022$39.65M+35.3%
Q4 FY2021Dec 31, 2021$36.75M+47.8%
Q3 FY2021Sep 30, 2021$39.88M+67.1%
Q2 FY2021Jun 30, 2021$35.95M+78.9%
Q1 FY2021Mar 31, 2021$29.30M+34.8%
Q4 FY2020Dec 31, 2020$24.87M+18.2%
Q3 FY2020Sep 30, 2020$23.86M+30.3%
Q2 FY2020Jun 30, 2020$20.10M+12.3%
Q1 FY2020Mar 31, 2020$21.74M-5.0%
Q4 FY2019Dec 31, 2019$21.03M-15.1%
Q3 FY2019Sep 30, 2019$18.32M-22.6%
Q2 FY2019Jun 30, 2019$17.91M-25.6%
Q1 FY2019Mar 31, 2019$22.89M-2.4%
Q4 FY2018Dec 31, 2018$24.77M+3.0%
Q3 FY2018Sep 30, 2018$23.68M+6.6%
Q2 FY2018Jun 30, 2018$24.05M+4.3%
Q1 FY2018Mar 31, 2018$23.46M+16.5%
Q4 FY2017Dec 31, 2017$24.04M+18.7%
Q3 FY2017Sep 30, 2017$22.21M-8.0%
Q2 FY2017Jun 30, 2017$23.06M–
Q1 FY2017Mar 31, 2017$20.14M–
Q4 FY2016Dec 31, 2016$20.26M–
Q3 FY2016Sep 30, 2016$24.14M–

More Seres Therapeutics figures

See a number that looks wrong?